Parkinson's Top News
the most important thing from 21.06.2022
Inbrija, the first inhaled levodopa is on the market.
The Deutsche Apothekerzeitung writes:
“Tremor, rigidity, bradykinesia – if the levodopa effect wears off, the typical symptoms reappear in Parkinson's patients. Inbrija is said to be the first inhaled levodopa to quickly improve these off-phenomena – it has been on the EU market since May.
Inbrija is approved® for some time: In September 2019, the European Commission approved the inhaled levodopa preparation, which Parkinson's patients can use to stop off symptoms, after the EMA's Committee for Medicinal Products for Human Use (CHMP) Inbrija® recommended for approval in July 2019. It is now coming onto the German market in May – it is the first inhaled levodopa (L-Dopa) ever.
Rapid relief of off symptoms
Parkinson's patients may use inhaled levodopa in addition to treatment Levodopa plus dopa decarboxylase inhibitors, such as benserazide or carbidopa, to intercept motor fluctuations – off-symptoms, i.e. phases with movement difficulties. Advantage of Inbrija® is that dopamine levels increase rapidly through inhalation and patients can quickly relieve their symptoms, which is the “Quality of life the patient improved,” explains the EMA to. For comparison: In the median is after two capsules Inbrija® (66 mg levodopa) the maximum L-dopa plasma concentration after 30 minutes, with immediate-release carbidopa/levodopa tablets (25 mg/100 mg) after 45 minutes.
Indication according to technical information
"Inbriya® is used for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease who are being treated with levodopa and a dopa decarboxylase inhibitor.
Before starting therapy, patients should already be on a stable dose of levodopa/carbidopa or levodopa/benserazide. They must also be able to recognize the symptoms of an off phase.”.
Source: https://www.deutsche-apotheker-zeitung.de/news/artikel/2022/05/12/inbrija-erstes-levodopa-zur-inhalation-auf-dem-markt
21.06.2022
Leave a comment
Participate in the discussion?Leave us your comment!